Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients by van Eijndhoven, Monique A J et al.
  
 University of Groningen
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients
van Eijndhoven, Monique A J; Zijlstra, Josée M; Groenewegen, Nils J; Drees, Esther E E; van
Niele, Stuart; Baglio, S Rubina; Koppers-Lalic, Danijela; van der Voorn, Hans; Libregts, Sten
F W M; Wauben, Marca H M
Published in:
Insight : the journal of the American Society of Ophthalmic Registered Nurses
DOI:
10.1172/jci.insight.89631
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Eijndhoven, M. A. J., Zijlstra, J. M., Groenewegen, N. J., Drees, E. E. E., van Niele, S., Baglio, S. R., ...
Pegtel, D. M. (2016). Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma
patients. Insight : the journal of the American Society of Ophthalmic Registered Nurses, 1(19), [e89631].
https://doi.org/10.1172/jci.insight.89631
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
1insight.jci.org   doi:10.1172/jci.insight.89631
C L I N I C A L  M E D I C I N E
License: This work is licensed under 
the Creative Commons Attribution 
4.0 International License. To view 
a copy of this license, visit http://
creativecommons.org/licenses/
by/4.0/.
Authorship note: D. de Jong and 
D.M. Pegtel contributed equally to 
this work.
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
Submitted: July 20, 2016 
Accepted: October 10, 2016 
Published: November 17, 2016
Reference information: 
JCI Insight. 2016;1(19):e89631. 
doi:10.1172/jci.insight.89631.
Plasma vesicle miRNAs for therapy 
response monitoring in Hodgkin 
lymphoma patients
Monique A.J. van Eijndhoven,1 Josée M. Zijlstra,2 Nils J. Groenewegen,1 Esther E.E. Drees,1  
Stuart van Niele,1 S. Rubina Baglio,1 Danijela Koppers-Lalic,1 Hans van der Voorn,3  
Sten F.W.M. Libregts,4 Marca H.M. Wauben,4 Renee X. de Menezes,5 Jan R.T. van Weering,6  
Rienk Nieuwland,7 Lydia Visser,8 Anke van den Berg,8 Daphne de Jong,1 and D. Michiel Pegtel9
1Department of Pathology, Exosomes Research Group, and 2Department of Hematology, VU University Medical Center, 
Amsterdam, Netherlands. 3iZON Science, Oxford, United Kingdom. 4Department of Biochemistry and Cell Biology, 
Utrecht University, Utrecht, Netherlands. 5Department of Epidemiology and Biostatistics, VU University Medical Center, 
Amsterdam, Netherlands. 6Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, 
Neuroscience Campus Amsterdam, VU University, Amsterdam, Netherlands. 7Department of Clinical Chemistry, Academic 
Medical Center, Amsterdam, Netherlands. 8Department of Pathology and Medical Biology, University of Groningen, 
University Medical Center Groningen, Groningen, Netherlands. 9Department of Pathology, Exosomes Research Group, VU 
University Medical Center, Amsterdam, Netherlands; ExBiome BV, Amsterdam, Netherlands.
Introduction
Most, if  not all, human tumors shed nucleic acids that end up in circulation, including DNA and mRNA/
microRNAs (mRNA/miRNAs), collectively called extracellular RNA (exRNA) (1, 2). This realization has 
prompted intensive studies to demonstrate the biomarker potential of exRNA in cancer patients, as it holds 
notable advantages over classic tissue biopsy sampling. The current gold standard for cancer detection in blood 
is analysis of circulating tumor DNA (ctDNA) (2). The ctDNA approach is attractive, as it may directly reflect 
BACKGROUND. Cell-free circulating nucleic acids, including 22-nt microRNAs (miRNAs), represent 
noninvasive biomarkers for treatment response monitoring of cancer patients. While the majority 
of plasma miRNA is bound to proteins, a smaller, less well-characterized pool is associated with 
extracellular vesicles (EVs). Here, we addressed whether EV-associated miRNAs reflect metabolic 
disease in classical Hodgkin lymphoma (cHL) patients.
METHODS. With standardized size-exclusion chromatography (SEC), we isolated EV-associated 
extracellular RNA (exRNA) fractions and protein-bound miRNA from plasma of cHL patients and 
healthy subjects. We performed a comprehensive small RNA sequencing analysis and validation 
by TaqMan qRT-PCR for candidate discovery. Fluorodeoxyglucose-PET (FDG-PET) status before 
treatment, directly after treatment, and during long-term follow-up was compared directly with EV 
miRNA levels.
RESULTS. The plasma EV miRNA repertoire was more extensive compared with protein-bound 
miRNA that was heavily dominated by a few abundant miRNA species and was less informative 
of disease status. Purified EV fractions of untreated cHL patients and tumor EVs had enriched 
levels of miR24-3p, miR127-3p, miR21-5p, miR155-5p, and let7a-5p compared with EV fractions 
from healthy subjects and disease controls. Serial monitoring of EV miRNA levels in patients 
before treatment, directly after treatment, and during long-term follow-up revealed robust, stable 
decreases in miRNA levels matching a complete metabolic response, as observed with FDG-PET. 
Importantly, EV miRNA levels rose again in relapse patients.
CONCLUSION. We conclude that cHL-related miRNA levels in circulating EVs reflect the presence of vital 
tumor tissue and are suitable for therapy response and relapse monitoring in individual cHL patients.
FUNDING. Cancer Center Amsterdam Foundation (CCA-2013), Dutch Cancer Society (KWF-5510), 
Technology Foundation STW (STW Perspectief CANCER-ID).
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tumor tissue, for example by detection of actionable mutations (3) or rearranged genes (4). Because not all 
human tumor types in all stages carry the same mutations and ctDNA may not always reach high enough 
levels for robust detection in circulation, alternatives based on exRNA molecules are under development (5–7).
In the case of  classical Hodgkin lymphoma (cHL), various limitations in analyzing ctDNA and/or 
exRNA can be considered. Most cHL tumors contain only a small proportion of  malignant Hodgkin/
Reed-Sternberg (HRS) cells of  B cell origin, and the bulk of  the tumor volume consists of  nonmalignant 
cells, mostly reactive immune cells (8). The sensitivity for detection of  tumor-specific translocations, muta-
tions, and numerical chromosomal changes may therefore be less favorable in cHL than in some other 
malignancies. Because fragmented ctDNA is likely derived from apoptotic/necrotic tumor cells, with a 
half-life estimated between 2 and 12 hours, ctDNA may or may not signify vital tumor (9). This is a major 
benefit of  fluorodeoxyglucose–PET/CT (FDG-PET/CT) imaging, which is currently used in clinical prac-
tice for cHL, as it detects active tumor and stroma. The reported positive predictive values of  PET/CT in 
cHL patients are generally lower relative to the negative predictive values (10). TARC (thymus and activa-
tion-regulated chemokine, also known as cysteine-cysteine ligand 17 [CCL17]) is a chemokine produced 
by HRS cells that may have a role in shaping a favorable immune microenvironment (11, 12). TARC levels 
are increased in the sera of  cHL patients and may also reflect tumor status, since elevated levels decrease 
during treatment in most clinical responders (13, 14).
Another class of  cHL biomarkers are small noncoding miRNAs (15); miR155, in particular, is a strong 
candidate, as its precursor transcript BIC is amplified in the malignant HRS cells (16). miRNAs regulate 
genes that control differentiation and proliferation of  human B cells, and perturbations in certain miRNA 
expression levels drive lymphomagenesis in vivo. For example, miR155 cooperates with c-MYC to pre-
vent germinal center B cells from undergoing MYC-induced apoptosis (17). At least a small proportion of  
tumor-expressed miRNAs are actively secreted via extracellular vesicles (EVs) that are thus derived from liv-
ing tumor cells (18, 19). EVs protect miRNAs from degradation by external RNAses and may help regulate 
gene expression in a non-cell-autonomous manner (20), promoting tumorigenesis (21). Moreover, EV-asso-
ciated miRNAs may be more stable than other circulating miRNA fractions (22). For these reasons, EV-as-
sociated miRNAs may be enriched in defined lymphoma-associated miRNA species and could therefore 
overcome limitations of  other approaches. Importantly, the advantages of  EV-associated miRNAs as cancer 
biomarkers over measurements in total plasma or protein/HDL fractions have not been investigated.
Although cure rates for cHL patients are generally favorable, some patients will relapse or develop side 
effects from radiation/chemotherapy. Upcoming treatment strategies are aimed at personalized and target-
ed therapy that requires sensitive biomarkers suitable for repeated monitoring. In this study, we explored 
the optimal exRNA fraction for therapy response monitoring in a cohort of  cHL patients by RNA sequenc-
ing (RNAseq) and qRT-PCR. The results suggest that EV-associated miR21-5p, miR127-3p, miR24-3p, 
let7a-5p, and miR155-5p report metabolic active tumor tissue with a high sensitivity. Analyzing serial sam-
ples from individual cHL patients before and after treatment and during long-term follow-up revealed that 
the levels of  candidate miRNAs drop and stay low in clinical responders as determined with FDG-PET. 
The potential utility of  an EV-based miRNA detection approach for response monitoring is discussed.
Results
Isolation of  EVs from plasma using size-exclusion chromatography. To measure putative lymphoma-associated 
miRNAs in circulation, we isolated EVs from plasma with size-exclusion chromatography (SEC) using a 
recently described procedure (23–25) (Supplemental Figure 1, A and B; supplemental material available 
online with this article; doi:10.1172/jci.insight.89631DS1). This method of  isolation was chosen, as 
it may reduce the signal from abundant plasma miRNA associated with contaminating protein/HDL 
derived from nontumor-related sources; this method has been proven to outperform most other methods 
(23, 26, 27). Electron microscopy (EM) shows that vesicle-like membrane structures that range mostly 
from 50 to 200 nm are present in undiluted SEC vesicle fractions 9 and 10 but are absent in protein/HDL 
fractions 20 and 21 (Figure 1A). Particle analysis using qNano (iZON), based on tunable-resistive pulse 
sensing (TRPS), revealed that fractions 9 and 10 are enriched in particles with a size distribution that 
matches the EM images. Importantly, particles of  this particular size range are close to absent in protein/
HDL (Figure 1B). To further confirm separation of  vesicle-like particles from other plasma components 
(protein/HDL, etc.) with another method, we performed high-resolution flow cytometry. Both vesicle 
and protein/HDL enriched SEC fractions (fractions 9 and 10, and 20 and 21, respectively) were labeled 
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with PKH67, a fluorescent lipid dye that intercalates into lipid bilayers, and succumbed to sucrose gra-
dient flotation to separate EVs from free dye and protein aggregates (28). In Figure 1C, we show that 
sucrose fractions C–E contain a highly enriched population of  PKH67-positive particles (present in SEC 
fractions 9 and 10) when compared with protein/HDL (present in SEC fractions 20 and 21). Notably, the 
high levels of  PKH67-positive events in protein/HDL enriched SEC fractions present in the high-density 
sucrose fractions A and B resemble nonfloating unincorporated PKH67 and protein aggregates (Figure 
1, C and D) (28). We also performed comparative qNano particle analysis on a small panel of  cHL 
patient plasma and plasma from healthy individuals. cHL patients seemed to have increased concen-
trations of  circulating EVs, and the “additional” cHL-associated EVs are smaller in diameter (Figure 1, 
E and F). Together, these data show that EVs can be selectively isolated from healthy and cHL patient 
plasma using the SEC methodology.
Figure 1. Size-exclusion chromatography separates extracellular plasma vesicles from protein/HDL. (A) EM images of plasma extracellular vesicles (EVs) 
and protein/HDL fraction after size-exclusion chromatography of 1.5 ml healthy donor plasma. Scale bar: 200 nm. (B) Particle analysis using qNano (iZON) 
of plasma EV (red) and protein/HDL fraction (blue). (C) High-resolution flow cytometry (BD Influx) of plasma EV (black) and protein/HDL fraction (gray) 
after pkh67 fluorescent labeling followed by sucrose gradient centrifugation. (D) Scatter plots of plasma EV and protein/HDL fraction corresponding with 
sucrose gradient fraction D, as shown in C. (E) qNano particle analysis of plasma EV from a healthy donor and a cHL patient. (F) Particle concentration and 
size using qNano. n = 3 healthy donors and cHL patients. Error bars represent mean ± SEM; dots indicate individual samples.
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miRNAs are differentially distributed over plasma EVs and protein/HDL. To determine the noncoding 
exRNA pool in plasma using stem-loop qRT-PCR, we compared the miRNA abundance in 26 fractions 
that were collected by SEC of  1.5 ml of  healthy donor plasma. We measured the levels of  the previously 
identified EV-associated miRNAs miR142-3p and let7a-5p (25) and the small ncRNA vtRNA1-1 pre-
viously found enriched in EVs (29). Both miRNAs and vtRNA1-1 were approximately 100-fold higher 
in vesicle-enriched SEC fractions 9 and 10 (Figure 2, A and C). In contrast, miR92a-3p, miR21-5p, and 
miR451-5p seemed more equally distributed over the different SEC fractions (Figure 2, B and D). When 
comparing plasma with sera, plasma appears better suited for separating vesicle-associated small exRNAs 
from the protein/HDL-bound exRNAs. Overall exRNA levels appear higher in plasma compared with 
sera when using an equal amount of  volume as input material (Supplemental Figure 1C). To determine 
if  the SEC method enriches for small RNAs, we analyzed 1.5 ml culture supernatant from transformed 
B cells for the vesicle-associated ncRNA vtRNA1-1 we found previously (29). As shown in Figure 2E, 
vtRNA1-1 is highly enriched in vesicle fractions 9 and 10 compared with protein/HDL fractions 20 and 
21. To determine the recovery of  tumor EVs in circulation using the SEC approach, we “spiked” purified 
lymphoma exosomes (from an Epstein-Barr virus–transformed [EBV-transformed] B cell line) in 1.5 ml 
plasma from a healthy EBV-negative donor. In Figure 2F, we showed that the recovery of  exosome-asso-
ciated EBV miRNAs BHRF1-3 and BART2-5p is 10- to 15-fold higher in EV fractions 9 and 10 compared 
Figure 2. Small RNA distribution and recovery in EV fractions 9 and 10. (A and B) RNA distribution of miR142-3p, let7a-5p, and vtRNA1-1 (A) and miR92a-3p, 
miR21-5p, and miR451-5p (B) in 26 fractions upon size-exclusion chromatography (SEC) of 1.5 ml healthy donor plasma. Total RNA was isolated with TRIzol fol-
lowed by RT-PCR. Data are depicted as raw Ct values; error bars represent SEM from PCR duplicates. (C) Fold enrichment of vtRNA1-1, let7a-5p, and miR142-3p in 
plasma extracellular vesicles (EVs) (fractions 9 and 10) compared with protein/HDL (fractions 20 and 21). Data are shown as the mean of 2 donors; dots indicate 
individual samples. (D) Fold enrichment of miR92a-3p, miR21-5p, and miR451-5p in protein/HDL (fractions 20 and 21) compared with plasma EVs (fractions 9 
and 10). Data are shown as the mean of 2 donors; dots indicate individual samples. (E) Fold enrichment of vtRNA1-1 in tumor EV (tEV; fractions 9 and 10) com-
pared with protein/HDL (fractions 20 and 21) after SEC of 1.5 ml B cell culture supernatant. (F) SEC of 1.5 ml healthy donor plasma after spike in with 50 μl tumor 
cell line–derived exosomes. Shown is the fold increase of EBV-miR BHRF1-3 and BART2-5p in EV (fractions 9 and 10) compared with protein/HDL (fractions 20 
and 21). Data are shown as the mean of the 2 consecutive SEC fractions; dots represent individual fractions (E and F).
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with protein/HDL fractions 20 and 21. Thus, single-step SEC is a robust method to enrich for lymphoma 
cell–secreted EVs and useful for detection of  associated miRNAs.
RNAseq identifies lymphoma-associated miRNAs in plasma vesicles of  cHL patients. To identify EV-associated 
miRNAs in EV fractions, we performed small RNAseq on purified EVs from 6 different lymphoma cell 
lines that are of  B cell origin. We discovered a high number of  reads (reads per million) of  miR155-5p, 
miR21-5p, and let7a-5p that are highly expressed in lymphoma tissue and involved in lymphomagenesis 
(5, 16, 30, 31). Moreover, we found that miR127-3p and miR24-3p are abundant in EVs from the Hodgkin 
lymphoma cell lines L1236 and KMH2 (Figure 3A). Next, we verified whether these candidate miRNAs 
could be identified in plasma EV fractions from cHL patients. Total RNA was isolated from cHL patients 
and healthy individuals and analyzed using an Agilent small RNA chip (Supplemental Figure 1D). The 
bioanalyzer profiles have a typical small RNA shape, as seen before in purified EVs (32). With a HiSeq 
2500 (Illumina) device, 12 libraries were measured from 4 sample groups: (group I) protein fractions from 
3 healthy subjects, (group II) protein fractions from 3 cHL patients, (group III) EV fractions from 3 healthy 
subjects, and (group IV) EV fractions from cHL patients. The libraries were sequenced (single-end 50-bp 
read length), and reads were mapped to the human genome with the sRNAbench small RNA analysis 
pipeline we developed previously (29). The analysis yielded a total of  15 million reads that were, how-
ever, unevenly distributed between the 4 groups (Supplemental Table 1) but similar between individual 
samples within each group. The distribution of  small RNA classes was comparable in the EVs from cHL 
patients and healthy controls (Figure 3C), with 16%–67% of  the total mapped reads belonging to the class 
of  miRNAs in these groups (groups III and IV). In protein fractions (groups I and II), the large majority 
Figure 3. RNAseq reveals lymphoma-secreted miRNAs in circulating extracellular vesicles. (A) RNAseq analysis of miR24-3p, miR127-3p, miR155-5p, 
miR21-5p, and let7a-5p in extracellular vesicles (EVs) isolated from B cell lymphoma cell lines. Data are shown as reads per million miRNA reads (RPM). 
(B) Number of different miRNAs identified in plasma EV and protein/HDL fractions of healthy donors and cHL patients (n = 3 each). *P < 0.05 (unpaired 
2-tailed t test). (C) Distribution of small RNA subclasses in plasma EVs of a healthy individual and a cHL patient. Data shown are of 1 representative donor 
(n = 3) and depicted as percentage read counts. (D) RNAseq analysis of let7a-5p, miR21-5p, miR127-3p, and miR486-5p in healthy and cHL patient plasma 
EVs and protein/HDL fractions. Dots represent individual samples; error bars represent mean ± SEM. Reads are normalized using the trimmed mean of M 
values (TMM) method. (E) As in D, but data are shown as summed read counts.
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of  read counts belonged to the class of  miRNAs reaching 90% in the protein fractions of  healthy subjects 
(Supplemental Figure 2A). We identified the most miRNA species (415 species) in the EV fractions from 
cHL patients (group IV) compared with EVs from healthy individuals (202 species) (group III). Important-
ly, the amount of  different miRNAs identified in each cHL EV sample was significantly higher than that 
in healthy EV samples (P = 0.030), while, in each protein fraction, we detected fewer than 120 different 
species (Figure 3B). The numbers of  different miRNAs detected in each library did not correlate with the 
total miRNA read counts, suggesting that the differences are not merely caused by sequence depth but 
may reflect pathological conditions (Supplemental Figure 2E). In all groups, miR486-5p and miR92a-3p 
accounted for the majority of  miRNA reads (Supplemental Table 1), and these were the most pronounced 
in the protein fractions (Supplemental Figure 2B). This suggested that we detect more comprehensive 
miRNA repertoires of  cHL patients in EVs compared with protein-bound miRNAs.
Next, we wished to verify whether RNAseq analysis could identify lymphoma-associated miRNAs in 
EVs and/or protein/HDL fractions. We first applied a differential expression method connected to EdgeR 
software that uses a trimmed mean of  M values method for normalization. Consistent with the TaqMan 
RT-PCR data in Figure 2A, let7a-5p, an EV-associated miRNA, was highly enriched in EV groups III and 
IV, compared with the protein samples (groups I and II). Moreover, the normalized levels of  let7a-5p are 
significantly higher in cHL-associated EVs (group IV) compared with control EVs (group III) (P = 0.03), 
while let7a-5p levels in protein fractions of  patients (group II) and healthy controls (group I) were generally 
lower and not significantly different (P = 0.27) (Figure 3D). While miR21-5p in EVs of  healthy individuals 
appears enriched compared with protein (confirming TaqMan PCR in Figure 2B), we only found a small 
difference in miR21-5p protein levels between patients and controls, while no differences are seen in either 
fraction for miR127-3p or miR486-5p (Figure 3D).
Because the optimal normalization method(s) for analysis of  plasma RNAseq data is not established, 
we and others reasoned that an equal volume input allows for comparisons to identify disease-associated 
alterations in miRNA levels (5, 33). Interestingly, the lymphoma-associated miRNAs let7a-5p, miR21-5p, 
and miR127-3p have elevated reads, comparing EV samples from cHL patients and healthy controls, while 
miR486-5p reads are equally abundant (Figure 3E). Moreover the read counts of  EV-related miR142-3p 
(25) are high in the EVs, corresponding with RT-PCR data. Although miR142-3p was barely detected in the 
protein fractions by RNAseq, RT-PCR revealed low but detectable amounts (Figure 2A and Supplemental 
Figure 4. Study flow chart.
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Figure 2D). The summed reads representing cHL-associated miR24-3p and miR155-5p were elevated in 
patient EVs, while miR10b-5p values stood out as being particularly low in the cHL protein samples (Sup-
plemental Figure 2D).
To determine if  a correlation exists between the increased level of  cHL-associated miRNAs and a 
subtype of  plasma EVs, we performed RT-PCR analysis of  4 candidate biomarkers and determined con-
centration and size distribution with a qNano device (TRPS). As shown in Supplemental Figure 2C, the 
combined level of  miRNAs (miR127-3p, miR155-5p, miR21-5p, let7a-5p) corresponds with EV concentra-
tion, while a reverse correlation with EV size is noticeable in cHL patient plasma. These correlations were 
much less pronounced in healthy EVs.
In summary, RNAseq reveals that read numbers of  a small panel of  lymphoma-related miRNAs are 
increased in EVs from cHL patients, which was not seen in protein fractions. These differences could be 
related to a different EV composition and/or content in cHL patient plasma compared with healthy indi-
viduals. While these conclusions require further validation, RNAseq-based miRNA discovery in patient 
plasma can be readily performed using SEC-purified EV fractions as an exRNA source.
Candidate biomarker miRNAs are elevated in plasma vesicles of  cHL patients compared with healthy individuals. 
The RNAseq and RT-PCR data, combined with reports in the literature (5, 29, 30, 31, 34), suggested that 
miR127-3p, miR155-5p, miR21-5p, let7a-5p, and miR24-3p may represent noninvasive biomarkers for cHL. 
Next, we isolated EVs with the SEC method from 20 cHL patients prior to treatment and 9 healthy control 
subjects. The patient characteristics and requirements for inclusion  in clinical trials are summarized in Table 
1 and Figure 4. We extracted RNA from equal plasma volumes and determined miR127-3p, miR155-5p, 
miR21-5p, let7a-5p, and miR24-3p levels by the TaqMan (stem-loop) qRT-PCR method. We detected signifi-
cantly higher levels of  all candidate markers in patient samples compared with healthy controls (P = 0.0019, 
< 0.0001, 0.010, 0.0009, and 0.0017, respectively) (Figure 5, A–E). We also measured the level of  the known 
oncomiR miR-10b that is not known to be associated with cHL. Although we observe a slight increase, this 
is much less pronounced than for the lymphoma-associated miRNAs (Figure 5F).
As an additional control, we measured the miRNA levels in SEC-isolated plasma EVs from patients 
with a systemic autoimmune disease but did not detect any difference with the healthy controls (P = 
Table 1. Patient characteristics.
Patient characteristics Clinical trial No. of patients Percentage
At inclusion 20 100
Primary Hodgkin lymphoma 13 65
Relapsed Hodgkin lymphoma 7 35
Treatment (clinical trials) 19 95
ABVD HD16A 3 15
BEACOPPesc + ABVD HD17A 3 15
BEACOPPesc + rituximab HD18A 7 35
Allogenic PBSCT 1 5
DHAP + brentuximab vedotin + autologous SCT Transplant BRaVE 5 25
Follow-up 7 100
Primary Hodgkin lymphoma 5 71
Relapsed Hodgkin lymphoma 2 29
Treatment (clinical trials) 7 100
BEACOPPesc + ABVD HD17A 1 14
BEACOPPesc + rituximab HD18A 4 57
Allogenic PBSCT 1 14
DHAP + brentuximab vedotin + autologous SCT Transplant BRaVE 1 14
Response to treatment
CMR 6 86
No CMR 1 14
AGerman Hodgkin Study Group. ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPPesc, bleomycin, etoposide, adriamycin, 
cyclophosphamide, vincristine, procarbazine, and prednisone; PBSCT, peripheral blood stem cell transplantation; SCT, stem cell transplantation; CMR, 
complete metabolic response. 
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0.76 [miR127-3p], 0.73 [miR155-5p], 0.88 
[miR21-5p], and 0.25 [let7a-5p] (Supple-
mental Figure 3, A–D). Moreover, we did 
not observe different levels for the miRNA 
panel in healthy female and male subjects 
(Supplemental Figure 3, E–H). Important-
ly, we also detected high levels of  cHL-as-
sociated miRNAs in plasma EV fractions 
isolated from relapsed cHL patients (n = 
7) compared with healthy controls (P = 
0.013 [miR127-3p], 0.0022 [miR155-5p], 
0.012 [miR21-5p], 0.0013 [let7a-5p], and 
0.016 [miR24-3p], respectively) (Supple-
mental Figure 4, A–E). In contrast, the 
levels of  the control oncomiR miR10b-
5p (Supplemental Figure 4F) are more 
in range with those of  healthy subjects, 
which is consistent with RNAseq data 
(Supplemental Figure 2D). These obser-
vations strongly suggest that the panel of  
cHL-associated miRNAs could be useful for monitoring treatment response and relapse. In fact, when 
we used miR-10b levels for normalization, the levels of  miR127-3p, miR155-5p, miR21-5p, let7a-5p, 
and miR24-3p were significantly increased in the cHL patient population (P = 0.0025, 0.0005, 0.013, 
0.0030, and 0.0050, respectively) (Supplemental Figure 4, G–K). Thus, the differences observed are 
not due to more or less input of  EV and or RNA material, indicating our procedure of  isolation and 
miRNA detection is robust.
To ascertain whether it is important to measure the miRNA pool in plasma EVs specifically rather 
than in total plasma, we compared both approaches for miR127-3p and miR155-5p. In a side-by-side 
comparison of  the same sample set we showed that total plasma miR127-3p levels are not significantly 
different between patients and controls (P = 0.21) (Figure 6A). In contrast, measurements in the EV 
fraction of  the same patients showed that miR127-3p is significantly elevated (P = 0.0056) (Figure 6B). 
While miR155-5p was significantly increased in cHL patients versus controls when measured in total 
plasma and EV fractions (P = 0.0027 and 0.0030, respectively), fold differences were more robust in 
EVs (Supplemental Figure 5, A and B). Importantly, in a different patient cohort and using total sera as 
exRNA source, miR155-5p levels did not differ between cHL patients and healthy individuals (P = 0.16) 
(Supplemental Figure 5C). We determined the sensitivity and specificity of  miR127-3p in distinguish-
ing cHL patients before therapy from healthy individuals using ROC analysis. For miR127-3p, there 
seemed to be a substantial advantage in using plasma EV fractions as miRNA source (AUC = 0.80) 
(Figure 6D), since the same measurements in total plasma had no diagnostic value (AUC = 0.50) (Fig-
ure 6C). Thus, EV-associated circulating miRNAs seem more connected to the presence of  Hodgkin’s 
disease than the protein-bound miRNA pool.
Figure 5. Candidate miRNA levels are elevated 
in EVs of cHL patients compared with healthy 
controls. RT-PCR analysis of miR127-3p (A), 
miR155-5p (B), miR21-5p (C), let7a-5p (D), miR24-3p 
(E), and miR10b-5p (F) in plasma extracellular 
vesicles (EVs) of healthy individuals (n = 9) and 
cHL patients (n = 20) after size-exclusion chro-
matography (SEC) and total RNA isolation using 
TRIzol. For each individual sample, the mean Ct 
value of SEC fractions 9 and 10 was used. Boxes 
show the 25%–75% percentile; whiskers show 
the minimum-maximum; and lines represent the 
median. *P < 0.05; **P < 0.005; ***P < 0.0005; 
****P < 0.0001 (unpaired 2-tailed t test).
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miRNA levels in plasma vesicles of  
cHL patients correspond with clinical 
response to treatment. FDG-PET is 
the standard method for detecting 
tumor mass and monitoring clini-
cal response in cHL patients during 
active treatment and follow-up. The 
FDG-PET images depicted in Fig-
ure 7A show a reduction in vital 
tumor mass in a chemotherapy 
refractory patient. This patient was 
treated with second-line chemother-
apy, DHAP, and the antibody-drug 
conjugate brentuximab-vedotin and subsequently received an autologous stem cell transplant. We mea-
sured substantial decreases in miR127-3p, miR155-5p, miR21-5p, and let7a-5p in the plasma EV frac-
tion during and after treatment (t = 3 months) corresponding to FDG-PET status. Importantly, the 
miRNA levels remained stable for more than a year (t = 14 months) after initial diagnosis (t = 0). The 
decreased levels of  these miRNAs measured in EVs during treatment are therefore unlikely related to 
secondary effects of  the treatment (Figure 7, B–E). Similar results were observed in patients with pri-
mary tumor during and after first-line treatment (data not shown). In one patient that presented with 
relapsed disease, FDG-PET imaging revealed disappearance of  metabolic tumor activity after allogenic 
stem cell transplant; however, after 12 months, tumor tissue reappeared, suggesting incomplete meta-
bolic remission (Figure 7F). Notably, the levels of  miR127-3p, miR155-5p, and let7a-5p in plasma ves-
icles initially decreased to “normal” levels upon treatment; miR21-5p stood out, as it dropped by 60%, 
while, on average, levels dropped >80%–90% in patients with complete metabolic response (CMR). In 
full correspondence with PET imaging, 3–4 miRNAs were increased dramatically at 15 months (Figure 
7, G–J). These data illustrate that plasma vesicle-associated miRNAs are useful for monitoring cHL 
patients, as they reflect the presence of  vital tumor tissue.
To determine if  circulating EV miRNAs outperform total plasma miRNAs in monitoring response 
to therapy, we analyzed samples from 7 cHL patients before and after therapy. On average miR127-3p 
and miR155-5p levels decreased in total plasma (4-fold and 2-fold, respectively, P = 0.0052 and 0.016) 
(Figure 8, A and C). However, the decrease was more pronounced when measured in isolated EV 
fractions (11-fold and 4-fold, respectively, P = 0.0014 and 0.0016) (Figure 8, B and D). Importantly, 
when examining the individual patients, plasma EV-associated miRNAs were much better suited for 
monitoring response to (first-line and second-line) treatment compared with total plasma. In one cHL 
Figure 6. miR127-3p EV outperforms 
total plasma in distinguishing cHL 
patients from controls. (A) RT-PCR 
analysis of miR127-3p in total plasma of 
healthy controls (n = 7) and cHL patients 
(n = 8) after RNA isolation using TRIzol-LS. 
(B) RT-PCR analysis of miR127-3p in 
extracellular vesicle (EV) fractions of 
the same healthy individuals and cHL 
patients as in A after size-exclusion 
chromatography (SEC) and total RNA 
isolation. For each individual, the mean 
Ct value of SEC fractions 9 and 10 is 
used. (A and B) Boxes show the 25%–
75% percentile; whiskers show the mini-
mum-maximum; and lines represent the 
median. **P < 0.005 (unpaired 2-tailed t 
test). (C and D) ROC curves of miR127-3p 
in total plasma (C) and EV fractions (D) 
of the same healthy individuals and cHL 
patients as in A and B.
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patient with a primary tumor, miR127-3p, miR155-5p, and miR21-5p in EVs decrease markedly upon 
BEACOPP treatment (Figure 8F, gray), consistent with CMR. However, miR127-3p, miR155-5p, and 
miR21-5p levels in total plasma either remained stable or slightly increased (Figure 8E, gray). Similarly, 
in a relapsed cHL patient treated with second-line chemotherapy, DHAP, and brentuximab-vedotin, 
followed by autologous stem cell transplant, miR127-3p, miR155-5p, and miR21-5p in EVs (Figure 8F, 
black) decreased robustly upon treatment compared with a modest decrease of  total plasma levels (Fig-
ure 8E, black). Thus, miRNAs in plasma EV fractions are suitable for response to therapy in individual 
cHL patients. Indeed, we observed a 3- to 10-fold reduction in miR127-3p, miR155-5p, miR21-5p, and 
let7a-5p levels in the EV fractions when using equal volume input (Figure 8, G–J). This corresponded 
with CMR, as determined by FDG-PET in 6 of  7 patients. As mentioned, in one patient who did not 
show CMR after 1 year, we observed an increase in miRNA levels in plasma vesicles (Figure 7, F–J).
TARC is highly expressed in HRS cells that form a small minority of  the cHL tumor mass (11, 12). 
TARC levels are highly increased in cHL patient sera and plasma, and these levels decrease in most clinical 
responders (13, 14). We analyzed TARC levels using a standard ELISA assay in matched serum samples 
of  7 cHL patients before and after treatment with ELISA. Crucially, we observed substantial decreases in 
TARC levels of  the same 7 patients (Figure 8K) that have decreased miR127-3p, miR155-5p, miR21-5p, 
and let7a-5p in plasma vesicles.
Figure 7. Candidate miRNA markers in plasma EVs correspond with clinical response to treatment. (A) FDG-PET imaging of a cHL patient at initial 
diagnosis, during treatment, and at follow-up 4 months after initial diagnosis. T, tumor. Arrows indicate the location of tumor masses at initial diagnosis. 
(B–E) RT-PCR analysis of miR127-3p (B), miR155-5p (C), miR21-5p (D), and let7a-5p (E) in plasma extracellular vesicles (EVs) of the same cHL patient as in 
A at diagnosis (t = 0), at the end of treatment (t = 3 months), and at long-term follow-up (t = 14 months). Data are shown as a relative decrease compared 
with t = 0. Dots represent the mean ± SEM of the 2 consecutive size-exclusion chromatography fractions. (F–J) As in A–E, but for a cHL patient who did not 
reach complete metabolic response. The asterisk indicates a relative low decrease compared with other patients measured.
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Discussion
To improve patient care of  lymphoma 
patients by reducing the risk of  relapse, 
accurate knowledge of  vital tumor status 
during treatment is necessary for informed 
clinical decision-making. Despite a subop-
timal positive predictive value, radioactive 
FDG-PET is currently the method of  choice 
for monitoring therapy response and relapse 
in cHL (35–37). Molecular tests that can be 
issued repeatedly without adverse effects 
might complement the imaging methods for 
cHL patients to improve care. We applied 
RNAseq and TaqMan qRT-PCR on puri-
fied plasma vesicles (EV) and protein/HDL 
fractions and identified a small panel of  
cHL-related miRNAs (miR21-5p, miR127-
3p, let7a-5p, miR155-5p, and miR24-3p) in 
the EV fractions of  patients. We tested this 
panel for its utility as a potential therapy 
response tool in primary and relapsed cHL 
patients. We observed that the abundance of  
these EV-associated miRNAs consistently 
and stably dropped in patients with CMR to 
treatment. However, in one patient receiv-
ing allogenic stem cell transplant, miRNA 
levels initially dropped, corresponding with 
FDG-PET, suggesting remission. Howev-
er, miRNA levels increased after 1 year, in 
parallel with the reappearance of  nodules in 
Figure 8. EV outperforms total plasma for moni-
toring treatment response and corresponds with 
TARC. (A) RT-PCR analysis of miR127-3p in total 
plasma of cHL patients (n = 7) before and after 
treatment, after RNA isolation using TRIzol-LS. 
(B) RT-PCR analysis of miR127-3p in plasma extra-
cellular vesicles (EVs) of the same cHL patients (n 
= 7) as in A, after size-exclusion chromatography 
(SEC) and total RNA isolation. For each individ-
ual, the mean Ct value of SEC fractions 9 and 10 
is used. Boxes show the 25%–75% percentile; 
whiskers show the minimum-maximum; and lines 
represent the median. (C and D) As in A and B, 
but for miR155-5p. (E and F) RT-PCR analysis of 
miR21-5p, miR155-5p, and miR127-3p in total plas-
ma (E) and in plasma EVs (F) of an individual cHL 
patient with primary tumor before and after first-
line treatment (gray symbols) and a cHL patient 
with relapsed disease before and after second-line 
treatment (black symbols). (G–J) RT-PCR analysis 
of miR127-3p (G), miR155-5p (H), miR21-5p (I), and 
let7a-5p (J) in plasma EVs of cHL patients before 
and after treatment (n = 7). Each data point is the 
mean Ct value of the 2 consecutive SEC fractions 
9 and 10. (K) Serum TARC levels in the same cHL 
patients as in G–J before and after treatment, as 
measured by ELISA. Data are shown as paired 
before and after therapy samples (E–K).
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the chest (Figure 7, F–J). Our study suggests that analysis of  the exRNA repertoire in EVs holds advan-
tages over exRNA analysis from total plasma for response monitoring in cHL patients.
While ctDNA is the gold standard for liquid biopsy approaches in clinical cancer care (2, 3, 9), a 
potential drawback in a cHL setting is that malignant HRS cells bearing specific mutations are rare and 
driver mutations are infrequent (8). Moreover, the mutational landscape of  cHL is diverse, and the malig-
nant stroma is a crucial cofactor that is ignored with mutation-based ctDNA approaches (9). Apart from 
tumors shedding DNA fragments, intact and stabilized miRNAs are actively secreted into circulation from 
tumor cells (5, 25, 38). In fact, circulating plasma miRNAs were recently considered as potential therapy 
response biomarkers in cHL, although in this study, the candidate miRNAs were identified in cHL tissues 
first and then evaluated for monitoring purposes in unfractionated total plasma. The miRNA alterations 
measured in diseased tissues may not necessarily translate into alterations that can be measured in total 
plasma, in which cell-free miRNAs have a high dynamic range (39). Nondisease-specific stabilization of  
abundant miRNAs by proteins or heterogeneous expression lowers the sensitivity for detecting tumor-as-
sociated miRNAs (25).
We hypothesized that cHL tissues secrete a mixed population of  tumor-derived EVs that bring lym-
phoma-associated miRNAs into circulation where they are protected from degradation. To screen for 
candidates, we performed RNAseq analysis on EVs from tumor cells and directly on circulating EVs that 
were isolated with SEC. SEC is a promising method (23–25) that yields highly enriched populations of  
plasma EVs (Figure 1). We “rediscovered” miR21-5p as a potential candidate miRNA that is increased 
in circulation and overexpressed in cHL tissues (5). We further identified miR24-3p, miR127-3p, and 
let7a-5p in circulating EVs that were not identified by array profiling analysis of  cHL tissues (5). How-
ever, these miRNAs are expressed in multiple lymphoma cell lines as shown previously (31), including 
HRS cells (this study) (Figure 3A). Despite a limited sample size, we found increased concentrations of  
EVs in the plasma of  cHL patients compared with healthy controls that were generally smaller in the 
size (Figure 1F). This was consistent with increased detection of  EV-associated miR142-3p and let7-5p 
by both qRT-PCR and RNAseq (Figure 2, A and C; Figure 3, D and E; and Supplemental Figure 2D). 
While miR142-3p levels are not increased in EV fractions from cHL patients compared with healthy EVs 
(Supplemental Figure 2D), let7a-5p seems much more abundant in patient EVs (Figure 3, D and E). In 
fact, when we measured the candidate miRNAs, miR127-3p, miR155-5p, miR21-5p, and let7a-5p, by 
TaqMan RT-PCR in 3 patient samples, we observed a positive correlation of  the average Ct value with 
the plasma EV concentration, as measured by qNano (Supplemental Figure 2C). Our RT-PCR data and 
particle analysis combined suggest that EVs in circulation are heterogeneous, not only in size, but also in 
miRNA content, which is distinct from the protein-associated miRNA repertoire (40). Moreover, when 
we estimate the amount of  any given miRNA per vesicle we found a very similar stoichiometry as recent-
ly reported (40). We hypothesize that the concentration of  lymphoma-related miRNAs decreases in the 
EV fractions of  cHL patients during and after therapy, while nonlymphoma-related miRNAs are more 
stable in the EV fractions, such as miR10b-5p, mir142-3p, and miR486-5p.
The dynamic range of  plasma miRNAs is a big hurdle for biomarker discovery and validation. Typ-
ically, circulating small RNAs are discovered as cancer biomarkers in miRNA arrays, as the wide range 
of  concentrations of  different miRNAs in human plasma makes detection of  low abundant species with 
RNAseq in unfractionated plasma challenging (33, 41, 42). Our RNAseq results from small quantities 
of  RNA input confirm that miR486-5p and miR92a-3p are highly abundant miRNAs in human plasma 
(Supplemental Figure 2B) (25, 41). We nevertheless identified more than 400 miRNAs in the EV fractions 
from cHL patients and control subjects. Overall, the miRNA diversity in plasma EVs (60–250 different 
miRNAs per sample) seems higher compared with the protein/HDL fractions (60–110 different miRNAs 
per sample) (Figure 3B), although we cannot rule out that the detection of  low abundant species in protein 
fractions is hampered by the extreme abundance of  miR486-5p and miR92a-3p. Since the miRNA diversity 
did not correlate with total miRNA read counts (Supplemental Figure 2E), we presume that the observed 
differences are not a consequence of  sequencing depth alone but may be related to an underlying biolo-
gy. Thus, SEC-purified EV fractions are a preferred exRNA biosource for identification of  abundant and 
less-abundant miRNAs.
We found that EV-associated miR21-5p, miR127-3p, let7a-5p, miR24-3p, and miR155-5p signals were 
elevated in primary and relapsed cHL patients compared with healthy individuals. Previously, Jones and 
colleagues reported elevated levels of  miR21 and miR155 in total plasma of  cHL patients compared with 
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healthy control plasma (5). However, these authors did not document decreased miR155 levels during 
or after therapy, while we detected small, but significant, decreases (2-fold, P = 0.016) in unfractionated 
plasma after therapy. Nevertheless, the decrease in miR155-5p was more pronounced in the EV fraction 
(4-fold, P = 0.016) (Figure 8, C and D). We cannot exclude that the preanalytical conditions in the Jones 
study (samples were processed up to 24 hours after collection) may have obscured miR155 differences 
in total plasma (5). Our results suggest that most candidate miRNAs for treatment response monitoring 
measured in EVs outperform miRNAs found in total plasma increasing sensitivity and specificity. This 
was certainly true for the newly identified cHL marker miR127-3p, which was not previously linked to 
cHL when analyzing tumor tissue. miR127-3p is functionally involved in the B cell differentiation process 
through posttranscriptional regulation of  BLIMP1 and XBP1 genes (43). BLIMP was previously reported as 
a direct target of  let7a in HRS cells (44) and cooperates with miR127-3p in driving lymphomagenesis (34). 
We detected high levels of  miR127-3p in EVs produced by HRS cells in culture (Figure 3A) and in plasma 
EVs of  cHL patients but less abundant levels in healthy control EVs (Figure 5A). ROC analysis illustrated 
that EV-associated miR127-3p can distinguish cHL patients from controls (AUC = 0.80), while this is not 
the case when using total plasma as exRNA source (AUC = 0.50) (Figure 6, C and D). This suggests that 
the pool of  miR127-3p detected in the protein fraction is unrelated to cHL tumor tissue and is derived from 
other sources. It remains to be demonstrated whether miR127-3p levels in EVs reflect total expression of  
this miRNA in HRS cells, which are vital for the secretion of  this miRNA via EVs into circulation.
This study confirms the original discovery of  the value of  stabilized circulating miRNAs as cancer 
biomarkers (25, 38) and supports the recent observation that these are suited for serial testing to assess 
the kinetics of  response to therapy (39). The main advantage of  this study is that SEC-isolated EVs from 
plasma are compatible with RNAseq. Using RNAseq, we found evidence that miRNA measurements in 
EV fractions can increase the signal-to-noise ratio of  miRNA biomarkers in plasma. It is further clear that 
RNAseq normalization methods used for differential expression analysis in tissues need improvement, as 
these methods fail to identify low abundant candidate miRNAs in plasma EV and protein fractions. The 
procedure of  isolating EVs with SEC from plasma and miRNA detection by TaqMan PCR is easy to 
learn and robust, and no specialized laboratory equipment is needed. Thus, our approach is, in principle, 
compatible with routine diagnostic testing. While not the focus here, in the future, RNAseq as a detection 
platform seems promising (45). Our results warrant larger studies with longitudinal patient samples to 
assess the clinical utility of  EV miRNAs as a molecular diagnostic tool for treatment response, relapse, and 
potentially minimal residual disease monitoring for cHL patients.
Methods
Patients. Twenty patients with cHL were included (Figure 1); patient characteristics are summarized in 
Table 1. Seven of  twenty patients had relapsed disease at initial presentation. Interim and after treatment 
samples were available from 7 patients, up to 15 months after treatment initiation. Six of  seven patients 
showed CMR, as determined by 18F FDG-PET, and 1 patient did not reach complete remission. As con-
trols, 9 healthy donor plasma samples were used and additionally 4 patients with systemic lupus erythe-
matosus (SLE) were included. The SLE patient group consists of  patients with active disease as well as 
patients in remission. One patient received immune-suppressive drugs at time of  analysis.
Blood was collected in K2E (EDTA) tubes and serum collection tubes (BD Vacutainer) and processed 
within 2 hours after collection. Platelet-free plasma and sera were isolated as described in Supplemental 
Figure 1A and stored in 1.5-ml aliquots at –80°C until further analysis. Freeze-thaw cycles were avoided.
SEC. SEC was performed as described previously (23). Sepharose CL/2B (GE Healthcare) in 0.32% 
citrate/PBS was stacked in a BD syringe up to a 10-ml column bed volume, and this was used to separate 
vesicles and protein/HDL from 1.5 ml plasma, sera, or cell culture supernatant. Immediately after applying 
the samples onto the column, 26 fractions of  0.5 ml were collected and stored at –80°C at least overnight 
until further analysis (Supplemental Figure 1B). Fractions 9 and 10 are considered as vesicle-enriched frac-
tions, and fractions 20 and 21 as protein/HDL-enriched fractions. The fractions were processed and ana-
lyzed individually to serve as an internal duplicate. Notably, for SLE patient plasma, 0.5 ml was used for 
SEC, 0.32% citrate/PBS was added to adjust the volume up to 1.5 ml. Freeze-thaw cycles of  the fractions 
were avoided. EM was done as described previously (32).
Cell culture. Hodgkin lymphoma cell lines (L1236, KMH2), diffuse large B cell lymphoma cell lines 
(Ly3, Ly10, HL4, HL5; gifts from S. Cillessen [Department of  Pathology, VU University Medical Center, 
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Amsterdam, Netherlands]), and EBV-infected lymphoblastoid cell lines (IK140508, RN) were cultured in 
RPMI-1640 (Lonza), supplemented with 10% FBS (Hyclone), 100 U/ml penicillin G, 100 μg/ml strepto-
mycin sulfate, and 2 mM glutamine. Exosomes were isolated as described previously (46).
Spike in. B cell tumor–derived exosomes were isolated by differential ultracentrifugation as described 
previously (46). An EBV-infected B cell line (RN) was chosen to enable distinguishing spiked in exosomes 
from circulating plasma EVs. 50 μl exosomes were spiked into 1.5 ml plasma from an EBV-negative healthy 
donor prior to SEC. Fractions were collected and stored at –80°C until RNA analysis.
RNA isolation. Total RNA was isolated using TRIzol (Thermo Fisher Scientific) according to the man-
ufacturer’s instructions, with some modifications. 0.75 ml TRIzol was added to 0.25 ml SEC fractions, 
mixed properly, and incubated at room temperature for 15 minutes. Samples were stored at –80°C for at 
least 3 hours to increase the RNA yield from vesicle fractions specifically. Prior to isopropyl precipitation 
50 μg glycogen (Roche) was added. The final RNA pellet was dissolved in 10 μl nuclease-free water. For 
RNAseq, RNA from fractions 9 and 10 or 20 and 21 from 2.25 ml (for cHL patients) or 3.75 ml (for healthy 
controls) plasma was pooled in a final volume of  10 μl.
For RNA isolation of  total plasma or sera, 0.75 ml TRIzol-LS (Thermo Fisher Scientific) was added to 
0.25 ml plasma and further processed as described above.
Small RNAseq and analysis. The RNA quality from plasma EVs and protein/HDL fractions from cHL 
patients and healthy donors was analyzed on a Agilent 2100 Bioanalyzer using a small RNA chip. Maximum 
input (6 μl) was prepared for sequencing using the Illumina TruSeq small RNA Preparation Kit according to 
the manufacturer’s instructions. RNAseq was performed on a HiSeq 2500 (Illumina, single-end 50-bp read 
length), using equimolar amounts for each sample. Sequencing analysis was done by using the sRNAbench 
package as described previously (47). Briefly, after adapter trimming and unique read grouping, reads were 
aligned to the human genome (UCSC hg19) using Bowtie 1.1.2. To provide annotations for RNA elements 
that mapped to the human genome, several databases were used, including miRBase (version 21) for mature 
and pre-miRNA sequences and the NCBI Reference Sequences (RefSeq release 69, January, 2 2015). A 
differential expression module based on edgeR was used to generate an expression matrix of  all miRNAs 
detected (48) using trimmed mean of  M values normalization for the detection of  differentially expressed 
small RNAs (49). RNAseq on cell line–derived exosomes was done as described previously (29).
Multiplex stem-loop RT-PCR. Equal volumes of RNA (3 μl) were reverse transcribed using the TaqMan 
MicroRNA Reverse Transcription kit (Thermo Fisher Scientific). Equal volumes were used throughout to reduce 
technical variation, since an optimal normalizer for small RNAs in circulation has not been established (33).
Up to 5 RT-primers (TaqMan MicroRNA Assay, Thermo Fisher Scientific) were used in a multiplex 
reaction after checking their sensitivity and specificity in a singleplex and multiplex reaction. After cDNA 
synthesis nuclease-free water was added up to a final volume of  50 μl. 3 μl of  cDNA was subjected to 40 
cycles of  95°C for 15 seconds and 60°C for 1 minute on a ABI 7500 Fast system. All samples were mea-
sured in duplo, and the input for PCR was 13.5 μl plasma equivalents, with the exception of  SLE patient 
plasma (3.2–6.4 μl). Data were analyzed using 7500 Software v2.0.6, and, for comparison of  miRNA lev-
els, the Ct threshold was set at similar levels in different PCR runs. The following miRNA assays were used: 
miR127-3p (ID 000452), miR155-5p (ID 002623), miR21-5p (ID 000397), let7a-5p (ID 000377), miR24-3p 
(ID 000402), miR10b-5p (ID 002218), miR142-3p (ID 000464), miR92a-3p (ID 000431), and miR451-5p 
(ID 001105) (Thermo Fisher Scientific). ncRNA vtRNA1-1 and EBV miRNAs BHRF1-3 and BART2-5p 
were amplified as described previously (32, 50).
TARC analysis. Serum TARC was measured using a double antibody sandwich ELISA (R&D Systems) 
as described previously (13).
High-resolution flow cytometry. High-resolution flow cytometry was performed as described previously 
(28). Briefly, SEC fractions were fluorescently labeled with the lipid dye PKH67 (Sigma-Aldrich), and EVs 
were floated to their buoyant density by sucrose gradient flotation. Gradient fractions were subsequently 
analyzed for EV content by performing fluorescent threshold triggering on a BD Influx flow cytometer that 
was adapted for analysis of  nano-sized particles.
Particle analysis by TRPS. The concentration and diameter of  circulating vesicles were determined by 
TRPS using a qNano device (iZON). Samples were analyzed using 150-nm pore size and the average result 
of  pressures of  3, 5, and 8 mbar. All samples were measured in duplicate.
Statistics. A Kolmogorv-Smirnov test was used to check the Gaussian distribution, followed by unpaired 
2-tailed t test. Analyses were performed using Graphpad Prism 6 software. P values of  less than 0.05 were 
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considered significant. Leave-one-out cross-validation was used to produce predictions of  disease status per 
individual using a logistic regression model fitted to all remaining individuals, except the one predicted. Using 
the individual predicted probabilities, ROC curves and corresponding AUCs were produced per miRNA.
Study approval. Clinical investigation was conducted according to the Declaration of  Helsinki and 
approved by the VU University Medical Center medical ethical committee. All samples were obtained with 
written informed consent.
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